Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg

Hypertension Research

Volumn 38, Issue 5, 2015, Pages 329-335

  Rakugi, Hiromi ^a   Tsuchihashi, Takuya ^b   Shimada, Kazuyuki ^c   Numaguchi, Hirotaka ^d   Nishida, Chisato ^d   Yamaguchi, Hiroya ^d   Shirakawa, Masayoshi ^d   Azuma, Kyoichi ^d   Fujita, Kenji P ^e  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b STEEL MEMORIAL YAWATA HOSPITAL   (Japan)

^c Shin Oyama City Hospital   (Japan)

^d Merck Sharp Dohm Res Labs Japan   (Japan)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

amlodipine; hydrochlorothiazide; Japan; losartan

Indexed keywords

AMLODIPINE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN PLUS AMLODIPINE; LOSARTAN; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT;

ABNORMAL LABORATORY RESULT; ADD ON THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DEPRESSED BLOOD PRESSURE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPOKALEMIA; JAPANESE (PEOPLE); KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL; BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECTS; HYPERTENSION; JAPAN; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; JAPAN; LOSARTAN; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929070231     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2015.3     Document Type: Article

References (20)

1. Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ishimitsu T, Ito M, Ito S, Itoh H, Iwao H, Kai H, Kario K, Kashihara N, Kawano Y, Kim-Mitsuyama S, Kimura G, Kohara K, Komuro I, Kumagai H, Matsuura H, Miura K, Morishita R, Naruse M, Node K, Ohya Y, Rakugi H, Saito I, Saitoh S, Shimada K, Shimosawa T, Suzuki H, Tamura K, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Umemura S. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014). Hypertens Res 2014; 37: 253-387.
2. Mori H, Ukai H, Yamamoto H, Saitou S, Hirao K, Yamauchi M, Umemura S. Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res 2006; 29: 143-151.
3. Ohta Y, Tsuchihashi T, Kiyohara K. Relationship between blood pressure control status and lifestyle in hypertensive outpatients. Intern Med 2011; 50: 2107-2112.
4. Erdine S. How do compliance, convenience, and tolerability affect blood pressure goal rates? Am J Cardiovasc Drugs 2012; 12: 295-302.
5. Panjabi S, Lacey M, Bancroft T, Cao F. Treatment adherence, clinical outcomes, and economics of triple-drug therapy in hypertensive patients. J Am Soc Hypertens 2013; 7: 46-60.
6. Sakima A, Ohshiro K, Nakada S, Yamazato M, Kohagura K, Nakamoto M, Tana T, Ohya Y. Switching therapy from variable-dose multiple pill to fixed-dose single-pill combinations of angiotensin II receptor blockers and thiazides for hypertension. Clin Exp Hypertens 2011; 33: 309-315.
7. Neutel JM, Smith DH. Hypertension management: rationale for triple therapy based on mechanisms of action. Cardiovasc Ther 2013; 31: 251-258.
8. Liang K-L, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankyâ 2000; 62: 134-148.
9. Robins JM, Wang N. Inference for imputation estimators. Biometrika 2000; 87: 113-124.
10. Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics 1997; 53: 983-997.
11. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4: 213-226.
12. Lu K, Mehrotra DV, Liu G. Sample size determination for constrained longitudinal data analysis. Stat Med 2009; 28: 679-699.
13. Taylor AA, Ragbir S. Three in one: safety, efficacy, and patient acceptability of triple fixed-dose combination medicine in the management of hypertension. Patient Prefer Adherence 2012; 6: 555-563.
14. Rakugi H, Tsuchihashi T, Shimada K, Numaguchi H, Nishida C, Yamaguci H, Shirakawa M, Azuma K, Fujita KP. Efficacy and safety of triple therapy with losartan 50mg/hydrochlorothiazide 12.5mg/amlodipine 5mg in Japanese patients with essential hypertension: a randomized, controlled trial. Clin Exp Hypertens 2014 (e-pub ahead of print 1 October 2014; doi:10.3109/10641963.2014.954712).
15. He J, Whelton PK. Elevated systolic blood pressure as a risk factor for cardiovascular and renal disease. J Hypertens Suppl 1999; 17: S7-S13.
16. Maeda K, Adachi M, Kinoshita A, Koh N, Miura Y, Murohara T. Efficacy and safety of the losartan-hydrochlorothiazide combination tablet in patients with hypertension uncontrolled by angiotensin II receptor antagonist therapy: the Aichi Research on Combination therapy for Hypertension (ARCH) Study. Intern Med 2012; 51: 1167-1175.
17. Ohta Y, Tsuchihashi T, Onaka U, Eto K, Tominaga M, Ueno M. Long-term compliance with salt restriction in Japanese hypertensive patients. Hypertens Res 2005; 28: 953-957.
18. Kita T, Yokota N, Ichiki Y, Ayabe T, Etoh T, Tamaki N, Kato J, Eto T, Kitamura K. Three-year safety and effectiveness of fixed-dose losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension under clinical setting (PALM-1 Extension Study). Clin Exp Hypertens 2012; 34: 498-503.
19. Oshikawa J, Toya Y, Morita S, Taguri M, Hanaoka K, Hasegawa T, Kaizu K, Kamata K, Kobayashi S, Ohtake T, Sato T, Yasuda G, Kimura K, Umemura S. Angiotensin receptor blocker (ARB)-diuretic versus ARB-calcium channel blocker combination therapy for hypertension uncontrolled by ARB monotherapy. Clin Exp Hypertens 2014; 36: 244-250.
20. Oshikawa J, Toya Y, Morita S, Taguri M, Hanaoka K, Hasegawa T, Kaizu K, Kamata K, Kobayashi S, Ohtake T, Sato T, Yasuda G, Kimura K, Umemura S. Angiotensin receptor blocker (ARB)-diuretic versus ARB-calcium channel blocker combination therapy for hypertension uncontrolled by ARB monotherapy. Clin Exp Hypertens 2013; 36: 244-250.